Impact of potential modifications to Alzheimer’s disease clinical trials in response to disruption by COVID-19: a simulation study

[1]  Rebecca J Williams,et al.  Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances: The CONSERVE 2021 Statement. , 2021, JAMA.

[2]  A. Newman,et al.  Remote Research and Clinical Trial Integrity During and After the Coronavirus Pandemic. , 2021, JAMA.

[3]  D. Salmon,et al.  A survey of smartphone and interactive video technology use by participants in Alzheimer's disease research: Implications for remote cognitive assessment , 2021, Alzheimer's & dementia.

[4]  D. Bowers,et al.  Validity of teleneuropsychology for older adults in response to COVID-19: A systematic and critical review , 2020, The Clinical neuropsychologist.

[5]  A. Newman,et al.  Preserving Clinical Trial Integrity During the Coronavirus Pandemic. , 2020, JAMA.

[6]  E. Aguglia,et al.  Diagnostic and interventional implications of telemedicine in Alzheimer's disease and mild cognitive impairment: A literature review , 2020, International journal of geriatric psychiatry.

[7]  J. Mundt,et al.  Participant satisfaction with dementia prevention research: Results from Home-Based Assessment trial , 2018, Alzheimer's & Dementia.

[8]  D. Cohen,et al.  Publisher's Note , 2017, Neuroscience & Biobehavioral Reviews.

[9]  M. Sano,et al.  A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease , 2011, Neurology.

[10]  Ramon Diaz-Arrastia,et al.  High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. , 2008, JAMA.

[11]  D. Bennett,et al.  Vitamin E and donepezil for the treatment of mild cognitive impairment. , 2005, The New England journal of medicine.